Palisade Bio price target lowered to $8 from $22.50 at Maxim
The Fly

Palisade Bio price target lowered to $8 from $22.50 at Maxim

Maxim lowered the firm’s price target on Palisade Bio (PALI) to $8 from $22.50 and keeps a Buy rating on the shares. The company reported Q3 results with a net loss of ($3.5M) and ended the period with $8M in cash on the balance sheet, which should provide runway into Q2 of 2025, the analyst tells investors in a research note. Maxim anticipates another financing in the near-term, though it remains positive on the stock given the company returning to the clinic, the promising preclinical data, and the market opportunity in ulcerative colitis, the firm added.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App